NGL Fine Chem
NGL Fine Chem Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
European sales expected to generate INR25-30 crores in FY 26, with gradual growth thereafter. The company does not provide specific guidance on earnings, operating profits, or EPS due to market uncertainty and fluidity. - Revenue growth and margin improvement are expected to be gradual, especially from the regulated markets (U.S.
From NGL Fine Chem's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- European sales expected to generate INR25-30 crores in FY 26, with gradual growth thereafter. Meaningful growth anticipated from FY 27 onwards as regulated market scale-up takes 2-3 years.
- U.S. market sales likely to start significantly from FY 28, post product registrations and approvals.
- Volume growth of about 20% observed, though revenue growth is lower (~9%) due to pricing pressures.
- New capacity ramp-up will be gradual over FY 27 and FY 28, not abrupt.
- Sales potential from new capex is close to INR 300 crores, with an asset turn of 1.6x-1.7x expected.
2 more points from NGL Fine Chem's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what NGL Fine Chem said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing capex project with total outlay approx. INR 160 crores, targeted for completion by Q3 of the current financial year.
- Phase 1 of capex (including clean room and utilities) successfully commercialized; trial production and validations started.
- Capex financed through a 60:40 debt-equity ratio.
- Meaningful sales contribution expected from this new capacity starting FY 27 onwards.
- No other capex plans beyond this project currently.
- New plant will manufacture veterinary APIs.
2 more points from NGL Fine Chem's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders.
- However, it mentions onboarding 5 customers in the European Union for their products with some amount of business started, though not very large yet.
- Validation batches for new products targeting U.S. and European markets have started, with anticipated filings between October and December of the calendar year.
- Sales from Europe for FY26 are expected to be about INR 25-30 crores, indicating gradual ramp-up.
2 more points from NGL Fine Chem's call on order book
Pro opens every point from 15K+ earnings calls
NGL Fine Chem — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem's management said in earlier quarters
- Q3 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
NGL Fine Chem and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were NGL Fine Chem Q4 FY25 results?
European sales expected to generate INR25-30 crores in FY 26, with gradual growth thereafter. The company does not provide specific guidance on earnings, operating profits, or EPS due to market uncertainty and fluidity. - Revenue growth and margin improvement are expected to be gradual, especially from the regulated markets (U.S.
What is NGL Fine Chem share price analysis?
NGL Fine Chem currently shows a neutral. The stock trades at a P/E of 42.3 with a market cap of ₹2,135 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem planning capital expenditure?
Ongoing capex project with total outlay approx.
Keep NGL Fine Chem on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.